View Past Performance3-D Matrix バランスシートの健全性財務の健全性 基準チェック /563-D Matrixの総株主資本は¥5.2B 、総負債は¥575.0Mで、負債比率は11.1%となります。総資産と総負債はそれぞれ¥7.6Bと¥2.4Bです。 3-D Matrixの EBIT は¥158.0Mで、利息カバレッジ比率5.3です。現金および短期投資は¥2.1Bです。主要情報11.10%負債資本比率JP¥575.00m負債インタレスト・カバレッジ・レシオ5.3x現金JP¥2.10bエクイティJP¥5.18b負債合計JP¥2.39b総資産JP¥7.57b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026お知らせ • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.お知らせ • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025お知らせ • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.お知らせ • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025お知らせ • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.お知らせ • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025お知らせ • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025お知らせ • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024お知らせ • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.お知らせ • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024お知らせ • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.お知らせ • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.お知らせ • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024お知らせ • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023お知らせ • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023お知らせ • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023財務状況分析短期負債: DMTR.Fの 短期資産 ( ¥7.5B ) が 短期負債 ( ¥2.1B ) を超えています。長期負債: DMTR.Fの短期資産 ( ¥7.5B ) が 長期負債 ( ¥330.0M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: DMTR.F総負債よりも多くの現金を保有しています。負債の削減: DMTR.Fの負債対資本比率は、過去 5 年間で78.6%から11.1%に減少しました。債務返済能力: DMTR.Fの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。インタレストカバレッジ: DMTR.Fの負債に対する 利息支払い は EBIT ( 5.3 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 07:53終値2026/05/27 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋3-D Matrix, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.
お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026
お知らせ • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.
お知らせ • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025
お知らせ • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.
お知らせ • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025
お知らせ • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.
お知らせ • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025
お知らせ • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025
お知らせ • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024
お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024
お知らせ • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.
お知らせ • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024
お知らせ • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.
お知らせ • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.
お知らせ • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024
お知らせ • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023
お知らせ • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023
お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.
お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023
お知らせ • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023